Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2025-7454

Published: 2025

Journal Articles

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Ola Landgren, Benjamin Diamond, Abhishek Pandey, James Hoffman, David Coffey, Marcella Kaddoura, Brian Walker, Rabia Bukhari, Caterine Diaz, Stephanie Mompoint, Sindy Gutierrez, Kellye Koubek, Andrew Kowalski, Leslie Gallardo, Stephanie Fernandes, Sandra Mira, Massiel Cardo Lopez, Michelle Armogan, Dickran Kazandjian

Blood (2025) 146 (Supplement 1): 5775.

https://doi.org/10.1182/blood-2025-5775

Published: 2025

Journal Articles

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

Blood (2025) 146 (Supplement 1): 7479.

https://doi.org/10.1182/blood-2025-7479

Published: 2025

Journal Articles

Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes

Nathan Becker, Enze Liu, Zackary Sanborn, Attaya Suvannasankha, Kelvin Lee, Dickran Kazandjian, James Hoffman, Benjamin Diamond, Abhishek Pandey, Rafat Abonour, Ola Landgren, Lisa Munding, Aneta Mikulasova, Brian Walker

Blood (2025) 146 (Supplement 1): 3928.

https://doi.org/10.1182/blood-2025-3928

Published: 2025

Journal Articles

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Blood (2025) 146 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2025-3927

Published: 2025

Journal Articles

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Blood (2025) 146 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2025-3970

Published: 2025

Journal Articles

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

Blood (2025) 146 (Supplement 1): 251.

https://doi.org/10.1182/blood-2025-251

Published: 2025

Journal Articles

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Blood (2025) 146 (Supplement 1): 248.

https://doi.org/10.1182/blood-2025-248

Published: 2025

Journal Articles

On the cellular origins of multiple myeloma

Blood (2025) 146 (Supplement 1): 5694.

https://doi.org/10.1182/blood-2025-5694

Published: 2025

Journal Articles

Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.

Enze Liu, Nathan Becker, Sreejeta Mondal, Attaya Suvannasankha, David Coffey, Benjamin Diamond, Abhishek Pandey, Kelvin Lee, Dickran Kazandjian, Rafat Abonour, Aneta Mikulasova, Gareth Morgan, Ola Landgren, Brian Walker

Blood (2025) 146 (Supplement 1): 5693.

https://doi.org/10.1182/blood-2025-5693

Published: 2025

Journal Articles

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Blood (2025) 146 (Supplement 1): 5720.

https://doi.org/10.1182/blood-2025-5720

Published: 2025

Journal Articles

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Blood (2025) 146 (Supplement 1): 4052.

https://doi.org/10.1182/blood-2025-4052

Published: 2025

Journal Articles

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Ava Amidei, Benjamin Diamond, Elizabeth Lyubchenko, Stephanie Fernandes, Bahar Fard, Lubna Nousheen, Marc Arribas-Layton, Adam Sciambi, Dickran Kazandjian, James Hoffman, Abhishek Pandey, Marcella Kaddoura, Brian Walker, Ola Landgren, David Coffey

Blood (2025) 146 (Supplement 1): 2157.

https://doi.org/10.1182/blood-2025-2157

Published: 2025

Journal Articles

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2025-5763

Published: 2025

Journal Articles

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Blood (2025) 146 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2025-3920

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

Monoclonal gammopathy-related coagulopathies: A systematic analysis

Tessa Lavorgna, Thomas Plate, Diana Byrnes, Dickran Kazandjian, Benjamin Diamond, James Hoffman, Ola Landgren, Gerald Soff

Blood (2025) 146 (Supplement 1): 1305.

https://doi.org/10.1182/blood-2025-1305

Published: 2025

Journal Articles

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Blood (2025) 146 (Supplement 1): 4008.

https://doi.org/10.1182/blood-2025-4008

Published: 2025

Journal Articles

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

Blood (2025) 146 (Supplement 1): 7483.

https://doi.org/10.1182/blood-2025-7483

Published: 2025

Journal Articles

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Blood (2025) 146 (13): 1575–1585.

https://doi.org/10.1182/blood.2024028107

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

On the cellular origins of multiple myeloma

Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Monoclonal gammopathy-related coagulopathies: A systematic analysis

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only